Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Michael J. Bourque, the Executive Vice President, CFO, and Treasurer of Inogen Inc . (NASDAQ:INGN), recently disclosed a purchase of company stock valued at $24,960. The acquisition involved 3,000 shares of common stock at a price of $8.32 per share, completed on March 3, 2025. The purchase comes as the stock trades near $8.03, with InvestingPro analysis indicating the shares are currently undervalued.
In addition to the purchase, Bourque acquired a total of 60,225 shares in various transactions, including 600 shares through the company’s 2014 Employee Stock Purchase Plan and 47,625 shares as part of performance-based restricted stock unit awards. These shares were obtained at no cost. The insider buying occurs as the stock has experienced a significant 15.65% decline over the past week, despite the company maintaining strong liquidity with a healthy current ratio of 2.42.
However, Bourque also disposed of shares to cover tax liabilities associated with restricted stock unit awards. A total of 28,579 shares were withheld for tax purposes, with a transaction price of $8.33 per share, resulting in a total value of $238,063. Discover more insights about INGN’s valuation and 8 additional exclusive ProTips with InvestingPro.
Following these transactions, Bourque holds a total of 47,646 shares of Inogen common stock directly, representing a stake in the company’s $215.69 million market capitalization.
In other recent news, Inogen Inc. reported a significant earnings beat for the fourth quarter of 2024, with an earnings per share (EPS) of -$0.41, surpassing the forecast of -$0.61. The company also exceeded revenue expectations, reporting $80.08 million compared to the predicted $73.9 million. For the full year, Inogen achieved a revenue of $335.7 million, reflecting a 6.4% increase from the previous year. Inogen’s growth was primarily driven by substantial increases in business-to-business sales, both domestically and internationally, although direct-to-consumer sales saw a decline. Additionally, Inogen entered into a collaboration with UL Medical (TASE:BLWV), which included a $27 million investment, representing a 9.9% ownership stake in Inogen. This collaboration is expected to enhance Inogen’s product portfolio and expand its reach into the Chinese respiratory market. Analysts have noted these developments as positive, indicating potential for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.